Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy.
Celltrion has initiated enrolment of patients with mild symptoms of SARS-CoV-2 infection and the clinical trial is set to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of
The results were consistent in patients both with and without type 2 diabetes (T2D). CKD is a serious, progressive condition defined by decreased kidney function affecting nearly 700
Rocket Pharmaceuticals, a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that the U.S. Food and Drug Administration (FDA)
Under the deal, BeiGene will develop, manufacture and commercialise Singlomics’ investigational anti-Covid-19 antibodies, including DXP-593 and DXP-604, across the globe except for Greater China. By using single-cell sequencing
The study evaluates asciminib – a novel investigational treatment specifically targeting the ABL myristoyl pocket (STAMP) – in adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic
The highly differentiated antibody, HFB30132A, has been rapidly identified, engineered, and evaluated in multiple preclinical studies. A Phase I single-IV administration ascending dose study will assess the safety,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
